Home/BioFactura/Jeffrey N. Hausfeld, M.D., M.B.A., F.A.C.S.
JN

Jeffrey N. Hausfeld, M.D., M.B.A., F.A.C.S.

Chairman and Chief Medical Officer

BioFactura

BioFactura Pipeline

DrugIndicationPhase
BFI-751 (ustekinumab biosimilar)Autoimmune Diseases (e.g., psoriasis, Crohn's)Phase 1
Smallpox TherapeuticSmallpox infection (Biodefense)Pre-clinical/Development
Ebola TherapeuticEbola virus infection (Biodefense)Pre-clinical/Development
Novel Cancer Drug(s)CancerPre-clinical